November 29, 2005

Kaletra Monotherapy Shows Promise Again

November 29, 2005—In a small Spanish study, 81% of positive people maintained control of their HIV by taking Kaletra (a boosted protease inhibitor) alone for 72 weeks. The subjects in the study, reported last week at the Tenth European AIDS Conference in Dublin, had had undetectable HIV viral loads for at least six months on a combo of Kaletra and two nukes; then they stopped taking the nukes.